Search

Your search keyword '"Chitosan nanofibrous scaffold"' showing total 2 results
Start Over Descriptor "Chitosan nanofibrous scaffold"
2 results on '"Chitosan nanofibrous scaffold"'

1. Nanoparticle-containing electrospun nanofibrous scaffolds for sustained release of SDF-1α

Author

Frank Boury, Muhammad Haji Mansor, Mathie Najberg, Baya Gueza, Emmanuel Garcion, Carmen Alvarez-Lorenzo, Christine Jérôme, Rodolfo Molina-Peña, Jean-Michel Thomassin, Bernardo, Elizabeth, Design and Application of Innovative Local Treatments in Glioblastoma (CRCINA-ÉQUIPE 17), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Center for Education and Research on Macromolecules - CERM [Liège, Belgium], Université de Liège-CESAM RU [Liège, Belgium], SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques (ICAT), Université d'Angers (UA), Universidade de Santiago de Compostela [Spain] (USC ), Instituto de Investigación Sanitaria de Santiago de Compostela / Health Research Institute of Santiago de Compostela (IDIS), EuroNanoMed III (project GLIOSILK 'Silk-fibroin interventional nano-trap for the treatment of glioblastoma'), LabEx IRON 'Innovative Radiopharmaceuticals in Oncology and Neurology' as part of the French government 'Investissements d’Avenir' program, INCa (Institut National du Cancer) MARENGO consortium 'MicroRNA agonist and antagonist Nanomedicines for Glioblastoma treatment: from molecular programmation to preclinical validation' [Grant PL-BIO 2014-2020], French Région Pays-de-la-Loire (Bioimplants for Bone Regeneration (BILBO) part of the BIOREGATE Research-Training-Innovation consortium (RFI) and NanoFar +), Institut National de la Santé et de la Recherche Médicale (INSERM), University of Angers, France, Agencia Estatal de Investigación (AEI) and Instituto de Salud Carlos III (ISCIII) [AC19/00067] Cofinanciado FEDER, Spain, FEDER (FMF - Prostem) for the University of Liege (Liege, Belgium), Ministère de l'Enseignement supérieur, de la Recherche et de l’Innovation (MESRI), France, and European Project: AN33.32R

Subjects
Stromal cell, [SDV.BIO]Life Sciences [q-bio]/Biotechnology, Glioblastoma cell trap, Stromal cell-derived factor-1α (SDF-1α), [SDV]Life Sciences [q-bio], Nanofibers, Pharmaceutical Science, [SDV.CAN]Life Sciences [q-bio]/Cancer, Metastasis, chemistry.chemical_compound, Mice, [SDV.CAN] Life Sciences [q-bio]/Cancer, In vivo, medicine, Animals, Chitosan nanofibrous scaffold, [SDV.IB.BIO]Life Sciences [q-bio]/Bioengineering/Biomaterials, Tissue Scaffolds, Electrospinning, Chemistry, Adhesion, medicine.disease, In vitro, Chemokine CXCL12, Cell biology, Rats, PLGA, [CHIM.POLY]Chemical Sciences/Polymers, Delayed-Action Preparations, Cancer cell, NIH 3T3 Cells, Nanoparticles, Pseudopodia, Poly(lactic-co-glycolic acid) (PLGA) nanoparticles, Sustained release
Abstract

International audience; Chemokines such as stromal cell-derived factor-1α (SDF-1α) regulate the migration of cancer cells that can spread from their primary tumor site by migrating up an SDF-1α concentration gradient, facilitating their local invasion and metastasis. Therefore, the implantation of SDF-1α-releasing scaffolds can be a useful strategy to trap cancer cells expressing the CXCR4 receptor. In this work, SDF-1α was encapsulated into poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles and subsequently electrospun with chitosan to produce nanofibrous scaffolds of average fiber diameter of 261 ± 45 nm, intended for trapping glioblastoma (GBM) cells. The encapsulated SDF-1α maintained its biological activity after the electrospinning process as assessed by its capacity to induce the migration of cancer cells. The scaffolds could also provide sustained release of SDF-1α for at least 5 weeks. Using NIH3T3 mouse fibroblasts, human Thp-1 macrophages, and rat primary astrocytes we showed that the scaffolds possessed high cytocompatibility in vitro. Furthermore, a 7-day follow-up of Fischer rats bearing implanted scaffolds demonstrated the absence of adverse effects in vivo. In addition, the nanofibrous structure of the scaffolds provided excellent anchoring sites to support the adhesion of human GBM cells by extension of their pseudopodia. The scaffolds also demonstrated slow degradation kinetics, which may be useful in maximizing the time window for trapping GBM cells. As surgical resection does not permit a complete removal of GBM tumors, our results support the future implantation of these scaffolds into the walls of the resection cavity to evaluate their capacity to attract and trap the residual GBM cells in the brain.

Published
2021
Full Text
View/download PDF

2. Nanoparticle-containing electrospun nanofibrous scaffolds for sustained release of SDF-1α.

Author

Molina-Peña, Rodolfo, Haji Mansor, Muhammad, Najberg, Mathie, Thomassin, Jean-Michel, Gueza, Baya, Alvarez-Lorenzo, Carmen, Garcion, Emmanuel, Jérôme, Christine, and Boury, Frank

Subjects
*CXCR4 receptors, *CELL anatomy, *CONCENTRATION gradient, *FIBROBLASTS, *GLIOBLASTOMA multiforme, *CELL migration, *CELL adhesion
Abstract

[Display omitted] • Novel chitosan nanofibrous scaffold containing PLGA nanoparticles. • Electrospun nanofibers with SDF-1α-loaded nanoparticles for sustained release. • High cytocompatibility in vitro and in vivo and slow degradation profile. • Mat structure with good cell attachment of glioblastoma cells. • Bioimplant Intended as a sink for the trapping of CXCR4-expressing tumor cells. Chemokines such as stromal cell-derived factor-1α (SDF-1α) regulate the migration of cancer cells that can spread from their primary tumor site by migrating up an SDF-1α concentration gradient, facilitating their local invasion and metastasis. Therefore, the implantation of SDF-1α-releasing scaffolds can be a useful strategy to trap cancer cells expressing the CXCR4 receptor. In this work, SDF-1α was encapsulated into poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles and subsequently electrospun with chitosan to produce nanofibrous scaffolds of average fiber diameter of 261 ± 45 nm, intended for trapping glioblastoma (GBM) cells. The encapsulated SDF-1α maintained its biological activity after the electrospinning process as assessed by its capacity to induce the migration of cancer cells. The scaffolds could also provide sustained release of SDF-1α for at least 5 weeks. Using NIH3T3 mouse fibroblasts, human Thp-1 macrophages, and rat primary astrocytes we showed that the scaffolds possessed high cytocompatibility in vitro. Furthermore, a 7-day follow-up of Fischer rats bearing implanted scaffolds demonstrated the absence of adverse effects in vivo. In addition, the nanofibrous structure of the scaffolds provided excellent anchoring sites to support the adhesion of human GBM cells by extension of their pseudopodia. The scaffolds also demonstrated slow degradation kinetics, which may be useful in maximizing the time window for trapping GBM cells. As surgical resection does not permit a complete removal of GBM tumors, our results support the future implantation of these scaffolds into the walls of the resection cavity to evaluate their capacity to attract and trap the residual GBM cells in the brain. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results